Biosimilars are near-identical versions of biologic cancer drugs, available at lower costs. Germany saves hundreds of millions annually from just one biosimilar drug. Patient mistrust and policy ...

Oncology, ophthalmology, and pegfilgrastim biosimilars reached 81% market share within five years, while others lagged at 26%. CMS increased biosimilar reimbursement to ASP plus 8% of the originator's ...

ECCO’26 focused on holistic care for inflammatory bowel disease, with multiple presentations focusing on ustekinumab ...